20.09.2021 kl 10:34 3215

Particle-Enhanced Turbidimetric Immunoassay Market to Register Over 6% Growth through 2031
Published: Sep 20, 2021

As per latest Fact.MR analysis, the global particle-enhanced turbidimetric immunoassays (PETIA) market is set to register high growth between 2021 and 2031. Increasing prevalence of infectious diseases and growing interest in medical research are some of the major factors driving particle-enhanced turbidimetric immunoassays market.

Key players operating in the PETIA market are focusing on developing novel products using PETIA technique. They have developed various strategies such as advanced product launch, mergers and acquisitions to stay relevant in the market and expand their presence.

In August 2020, Gentian Diagnostics ASA added the Gentian Calprotectin Immunoassay (GCAL), the first turbidimetric assay for the quantitative measurement of calprotectin in plasma and serum intended as an aid in the detection and assessment of inflammation, to its catalogue.

In August 2020, TRIMERO Dianostics added new Serum Amyloid A, CE-IVD marked, particle-enhanced turbidimetric immunoassay to its catalogue.

In August 2020, Genetian Diagnostics ASA announced that it will launch COVID-19 antibody test using its unique PETIA technology. The Genetian antibody test will be a turbidimetric COVID-19 assay using the PETIA technology.

Some of the prominent manufacturers and suppliers operating in the particle-Enhanced turbidimetric immunoassays market profiled by Fact.MR are:

Gentian Diagnostics ASA
Thermo-Fisher Scientific
Abbott Laboratories
F.Hoffmann-La Roche
Siemens AG
Biomerieux SA

Rapportér innlegg

Vennligst skriv inn kommentar på hva du mener er upassende og trykk send. Dersom kommentar ikke er nødvendig, vennligst trykk send direkte.
E-postadressen brukes kun for å få kontakt med deg i forbindelse med advarselen.
E-postadressen brukes kun for å få kontakt med deg i forbindelse med advarselen.